Tocilizumab reduces hypercoagulation in COVID-19 – Perspectives from the coagulation and immunomodulation Covid assessment (Coag-ImmCovA) clinical trial
Tocilizumab reduces hypercoagulation in COVID-19 – Perspectives from the coagulation…
Ler MaisTocilizumab reduces hypercoagulation in COVID-19 – Perspectives from the coagulation…
Ler MaisRegulation of fibrinogen synthesis Dre’Von A. Dobson a), Richard J….
Ler MaisThe Attend-PE model: A feasibility study of a structured follow-up…
Ler MaisVenous thromboembolism in the era of machine learning and artificial…
Ler MaisImpact of anticoagulation therapy on outcomes in patients with cirrhosis…
Ler MaisAnticoagulants for the treatment of isolated lower limb superficial vein…
Ler MaisShared genetic etiology of vessel diseases: A genome-wide multi-traits association…
Ler MaisComparative effectiveness among thromboprophylaxis strategies after the Fontan operation: A…
Ler MaisEfficacy of unfractionated heparin in patients with moderate sepsis-induced coagulopathy:…
Ler MaisInvestigation of von Willebrand factor multimer abnormalities before and after…
Ler Mais